Human Genome Sciences

From Wikipedia, the free encyclopedia

Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs." The company focuses on drug development, as well as drug discovery and currently (as of 2006) has a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS.

Its facilities (called the Human Genome Sciences Headquarters) in Rockville, Maryland earned its architect—Davis Carter Scott, Ltd.—an award from the National Association of Industrial and Office Properties. The Association cited the glass walls, atrium, and uniform design of all the buildings as reasons for the award.

The company was founded by William Haseltine, a Harvard University AIDS researcher. Haseltine had a partnership for several years with Craig Venter to begin sequencing and submitting patents on thousands of pieces of DNA. In 2000, Haseltine said that his work "speeds up biological discovery a hundredfold, easily. Easily." He talked of finding in genes "the fountain of youth" in the form of "cellular replacement" therapies. More than $1 billion was invested in the company in 2000. But the drugs failed in initial clinical trials, and the stock plummeted.

For example, in September 2000, the company reported that it had found a way to treat large, painful sores that often plague elderly patients, using a protein spray called repifermin, made by a human gene called keratinocyte growth factor-2. Reporting on a Phase IIa clinical trial, Haseltine said "Those who got the drug grew almost 10 times as much skin as people who did not get any." In September 2003, the company reported that it would end the development of the drug for use in venous ulcers (sores) because of disappointing clinical trial results, but would continue a mid-stage (Phase II) trial of repifermin in the treatment of mucositis, an inflammation of the mouth that some chemotherapy patients develop. In February 2004, the company said that it was ending the development of repifermin because it showed no more benefit than a placebo in clinical trials.

Sources: